tiprankstipranks
Keros Therapeutics presents clinical data from Elritercept program at ASH
The Fly

Keros Therapeutics presents clinical data from Elritercept program at ASH

The company states: “Keros Therapeutics (KROS) announced that it presented additional data from its two ongoing Phase 2 clinical trials of elritercept, KER-050, one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes and one in patients with myelofibrosis, at the 66th American Society of Hematology Annual Meeting and Exposition (“ASH”), held in person in San Diego, California and virtually from December 7-10, 2024. This ongoing, open-label, two-part, Phase 2 clinical trial is evaluating elritercept in patients with very low-, low-, or intermediate-risk MDS. As of August 30, 2024, 95 patients had received at least one dose of elritercept at the recommended Part 2 dose. Of these patients in the safety population, 87 had completed at least 24 weeks of treatment or discontinued as of the data cut-off date (collectively, the modified intent-to-treat 24-week population, or the “mITT24 patients”). Data for hematological response and markers of hematopoiesis were presented from exploratory analyses of these mITT24 patients. Of the 95 patients in the safety population, 60.0% were high transfusion burden while 24.2% were low transfusion burden and 15.8% were non-transfused. Elritercept was generally well-tolerated in the safety population. There were four cases of fatal treatment-emergent adverse events in the trial that were all deemed unrelated to treatment. The most commonly reported TEAEs were diarrhea, fatigue, COVID-19, dyspnea, dizziness, anemia, nausea and epistaxis. One patient had progressed to acute myeloid leukemia as of the data cutoff date.”

Maximize Your Portfolio with Data Driven Insights:

  • Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
  • Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App